Sellas Life Sciences Group

Nasdaq SLS · New York, NY

Works in Cardiovascular · Dermatology · Genetic & rare · GI & liver · Hematology · Immunology · Metabolic & endocrine · Oncology · Renal & urogenital · Respiratory · Women's health

Sellas Life Sciences Group is a clinical trial sponsor based in New York, NY, listed as Nasdaq SLS. It has 2 active clinical trials with 287 planned participants, across 11 therapeutic areas. Since 2021 it has completed 4 trials and stopped 0 early.

Trial track record · since 2021

2Active trials287 planned participants
4Completed4 with results posted
0Stopped earlyterminated, withdrawn or suspended

Financials · Nasdaq SLS

Cash and equivalents
R&D expense
Net income (loss)
Cash runway

Fundraising

Pipeline · 2 active trials

StageTrialStatus

Questions about Sellas Life Sciences Group

See the rest of this profile

A free account shows the trial list, the financials and the fundraising filings. Pro adds a watchlist: one email when FDA acts on a company you name.

Trial counts are as the sponsor reported them to ClinicalTrials.gov, for trials changed since 2021; latest update 2026-09-03.

Approve Suite is not affiliated with Sellas Life Sciences Group.

See something wrong on this page? Write to info@approvesuite.com and we will check it against the source. How corrections work.